title: Paroxetine treatment of aggression and self-injury in persons with mental retardation.
abstract: An open, prospective assessment of the treatment of severe aggression and self-injurious behavior (SIB) with paroxetine, a serotonin re-uptake inhibitor, in 15 institutionalized persons with mental retardation was undertaken. Frequency and severity of aggression and SIB were charted by trained staff members. Only aggression severity was reduced over the entire 4-month follow-up period. Within the limits of an open trial, this effect was significant at one month but did not remain significant subsequently. The apparent diminution of effectiveness after 4 weeks of treatment may suggest adaptive changes warranting further study.
authors.affiliation: University of California at Los Angeles, USA. pdavanzo@ucla.edu
authors.forename: P A
authors.initials: PA
authors.lastname: Davanzo
authors.forename: T R
authors.initials: TR
authors.lastname: Belin
authors.forename: M H
authors.initials: MH
authors.lastname: Widawski
authors.forename: B H
authors.initials: BH
authors.lastname: King
mesh_terms: D000328:Adult; D000374:Aggression / Q000187:drug effects* / Q000523:psychology; D001321:Autistic Disorder / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology; D015897:Comorbidity; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology*; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D016728:Self-Injurious Behavior / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D012720:Severity of Illness Index; D019956:Stereotypic Movement Disorder / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors